Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.


Listen to the latest hemonc news from international experts

Texas MPN Workshop 2021: updates on interferons for MPNs

Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular for polycythemia vera, essential thrombocythemia and myelofibrosis. Interferon-alfa was originally explored for MPN treatment many years ago, however it’s frequent dosing and toxicity profile present barriers to widespread use. More recently, ropeginterferon-alfa-2b-vjft reported promising results for patients with polycythemia vera in the PROUD and CONTINUATION-PV clinical trials (NCT01949805; NCT02218047) and is now being reviewed for approval by the FDA. Pegylated-interferon-alfa has also demonstrated efficacy.

In this podcast, we hear from Richard Silver, MD, and Nicole Kucine, MD, MS, both from the Weill Cornell Medical College, New York, NY, who share the latest clinical updates on the use of interferons for the treatment of polycythemia vera and essential thrombocythemia, as presented at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

Date: 27th August 2021

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter